Ensocell

Ensocell is a Cambridge-based precision biologics company founded in 2023 by leading scientists from the Wellcome Sanger Institute, with operations at the Wellcome Genome Campus in Hinxton and in Alameda, California. The company's mission is to decode the complexity of human disease biology and identify novel therapeutic targets for autoimmune, inflammatory, and fibrotic diseases — conditions where existing broad-spectrum treatments have repeatedly failed patients.

The company's proprietary ENSO AI platform integrates single-cell and spatial genomics technologies with AI-based computational tools and advanced human cell models to identify disease intervention points that conventional research methods would miss. This multidisciplinary approach allows Ensocell to design precision biologics that are better matched to the actual biology of disease rather than its surface symptoms, with the aim of achieving higher clinical success rates than currently marketed therapies.

Ensocell raised $16.3 million in a funding round backed by OMX Ventures and Sofinnova Capital in 2024. The company draws on the scientific heritage of the Wellcome Sanger Institute, one of the world's foremost genomics research centres, and its founding team includes leading figures in single-cell genomics and computational biology.